Exploring the Role of Pharmacists as Facilitators of Harm Reduction Resources
April 1st 2024According to Anita Jacobson, PharmD, pharmacists should actively facilitate access to harm reduction programs by providing information and resources, ensuring the person who uses drugs doesn’t have to navigate the landscape on their own.
Pharmacists Should Adapt Harm Reduction Efforts to Address Unregulated Substances
April 1st 2024It’s important that pharmacists continuously revise their counseling as new information about substances such as xylazine, levamisole, and phenacetin emerges, said Anita Jacobson at this year’s American Pharmacists Association Annual Meeting & Exposition.
FDA Expands Tenofovir Alafenamide Indication to Treat HBV in Patients as Young as 6
March 28th 2024Tenofovir alafenamide was originally approved by the FDA in 2016 to treat adults with chronic HBV infection with compensated liver disease and in 2022 to treat pediatric patients aged 12 years and older.
Examining Trends in Long-Term Opioid Use, Importance of Pharmacist-Physician Collaboration
March 27th 2024At APhA 2024, 2 posters looked into how collaboration between physicians and community pharmacists is crucial when it comes to opioid prescriptions, and current opioid use patterns among older adults.
Psychedelic Therapeutics: Education, Advocacy Key to Overcoming Integration Hurdles
March 26th 2024According to Sa’ed Al-Olimat, education and advocacy are key to ensure a safe and accessible landscape of psychedelic therapeutics, especially as the compounds inch closer to the mainstream health care market.